Eli Lilly stock soars on strong demand for weight-loss drugs

Eli Lilly stock soars on strong demand for weight-loss drugs Ines Ferré · Senior Business Reporter Wed, August 5, 2026 at 3:53 PM GMT+2 1 min read LLY What happened: Eli Lilly ( LLY ) stock jumped as much as 7% on Wednesday. What's behind the move: The drug company raised its 2026 sales forecast after it saw strong demand for GLP-1 drugs in its fiscal second quarter. Revenue is now expected to fall between $85 billion and $87 billion for the year, topping an earlier forecast of up to $85 billion, according to Bloomberg data.

Adjusted earnings for the second quarter also beat Wall Street estimates. What else you need to know: Eli Lilly's GLP-1 business has been the growth engine of the drug company, benefiting from several tailwinds since the start of the year, including the FDA's approval of Foundayo, the pill version of its weight-loss drug, earlier this year. The company is also developing next-generation weight-loss medicine retatrutide.

It has clinical data in hand and plans to file for FDA approval in the first quarter of next year. More from Yahoo Scout What is retatrutide and its development timeline? What drove Eli Lilly's raised 2026 sales forecast?

How are GLP-1 drugs performing for Eli Lilly? How has Eli Lilly's stock performed recently? Shares of the drugmaker have rebounded from a first quarter slump, with the stock climbing more than 40% since the end of April and gaining 3% year to date, according to Yahoo Finance AlphaSpace data .

Ines Ferre is a Senior Business Reporter for Yahoo Finance covering the US stock market, publicly traded companies, and commodities. She has reported live from the floor of the New York Stock Exchange and Nasdaq. Follow her on X at @ines_ferre .

Click here for the latest trending stock tickers on the Yahoo Finance platform.